Boosting the Beneficial Non-specific Effects of Live Attenuated Vaccines: A Randomized Controlled Trial (RCT) of a Second Dose of Measles Vaccine (MV) in the Second Year of Life

NCT02943681 NA COMPLETED

This study evaluates the non-specific effects on child mortality and morbidity of a second dose of measles in the second year of life. Half of the study participants will receive a second dose of measles vaccine at 18 months of age while the other half will receive a second dose of measles by 4 years of age or at the end of the study.

Details

Lead sponsor	Bandim Health Project
Phase	NA
Status	COMPLETED
Enrolment	3812
Start date	2016-10
Completion	2021-05

Conditions

• Child Mortality
• Child Morbidity

Interventions

• Measles vaccine

Primary outcomes

• Mortality — 30 months
  Mortality registered monthly by Health and Demographic Surveillance System fieldworkers. Mortality will be combined with hospital admissions in the analysis to form the outcome severe morbidity. This will be examined overall and by sex
• Hospital admissions — 30 months
  Hospital admissions registered daily at the national hospital. Hospital admissions will be combined with mortality in the analysis to form the outcome severe morbidity. This will be examined overall and by sex

Countries

Guinea-Bissau